BioLineRx Ltd.
BLRX•NASDAQ•Healthcare•Biotechnology

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOPhilip Serlin
Founded2003
IPO DateJuly 25, 2011
Employees28
CountryIsrael
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.biolinerx.com
Phone972 8 642 9100
Address
Modi’in Technology Park, 2 HaMa’ayan Street Hevel Modi'in, 7177871 Israel

Corporate Identifiers

CIK0001498403
CUSIP09071M304
ISINUS09071M3043
SIC2834

Leadership Team & Key Executives

Philip A. Serlin CPA, M.B.A.
Chief Executive Officer
Mali Zeevi CPA
Chief Financial Officer
Dr. Ella Sorani Ph.D.
Chief Development Officer
John Lacey
Head of Corporate Communications and Investor Relations
Raziel Fried
Treasurer and Budgetary Control Director